HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Reports ‘Proliferation’ Of Cosmetics Making Drug Claims

This article was originally published in The Tan Sheet

Executive Summary

In a Consumer Update posted to its website, FDA suggests some cosmetic products “go too far” with their promises and urges consumers to be skeptical when faced with cosmetics making drug claims.

You may also be interested in...



Cosmeceutical Pioneer Strivectin’s ‘Anti-Aging Solutions’ Draw Drug Claim Warning

FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits.

FDA Remains Focused On Cosmetics Carrying Drug Claims – OCAC Director

At the American Conference Institute’s Legal, Regulatory and Compliance Forum on Cosmetics, FDA Office of Cosmetics and Colors Director Linda Katz discussed her division’s priorities for the year. On the enforcement front, OCAC will continue to focus on cosmetic products marketed with drug claims, she said.

California VOC Limits Will Challenge Industry To Maintain Fragrance Quality, Consumer Acceptance

The Fragrance Creators Association and Personal Care Products Council remain concerned that more stringent VOC limits for personal fragrance products in California, as approved by the Air Resources Board in March, will be disproportionately burdensome for industry and potentially detrimental to the market.

Topics

UsernamePublicRestriction

Register

RS123183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel